BELLUS Health Inc. (BLU)

NASDAQ: BLU · Delayed Price · USD
7.72
-0.35 (-4.34%)
At close: May 25, 2022 4:00 PM
8.10
0.38 (4.92%)
After-hours:May 25, 2022 6:29 PM EDT
Market Cap824.09M
Revenue (ttm)9,524
Net Income (ttm)-55.42M
Shares Out106.75M
EPS (ttm)-0.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume667,712
Open7.98
Previous Close8.07
Day's Range7.62 - 8.02
52-Week Range2.60 - 9.84
Beta-0.50
AnalystsBuy
Price Target12.85 (+66.5%)
Earnings DateMay 9, 2022

About BLU

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

IndustryBiotechnology
Founded1993
CEORoberto Bellini
Employees40
Stock ExchangeNASDAQ
Ticker SymbolBLU
Full Company Profile

Financial Performance

In 2021, BELLUS Health's revenue was 16,000, an increase of 6.67% compared to the previous year's 15,000. Losses were -71.22 million, 124.3% more than in 2020.

Financial numbers in millions CADFinancial Statements

Analyst Forecast

According to 10 analysts, the average rating for BLU stock is "Buy." The 12-month stock price forecast is 12.85, which is an increase of 66.45% from the latest price.

Price Target
$12.85
(66.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

1 week ago - Zacks Investment Research

Wall Street Analysts Believe Bellus (BLU) Could Rally 32%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive t...

1 week ago - Zacks Investment Research

BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

2 weeks ago - Business Wire

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 Inter...

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

3 weeks ago - Business Wire

BELLUS Health to Participate in Multiple Upcoming Investor Conferences

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

1 month ago - Business Wire

Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?

Here is how Bellus Health (BLU) and Innoviva (INVA) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

Can Bellus (BLU) Climb 70% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 70.5% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive t...

2 months ago - Zacks Investment Research

BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

2 months ago - Business Wire

Can Bellus (BLU) Climb 88% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at an 87.5% upside potential for Bellus (BLU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...

3 months ago - Zacks Investment Research

Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates

Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

BELLUS Health Reports Year 2021 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

3 months ago - Business Wire

All You Need to Know About Bellus (BLU) Rating Upgrade to Buy

Bellus (BLU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Wall Street Analysts Predict a 65% Upside in Bellus (BLU): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 65% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive tre...

3 months ago - Zacks Investment Research

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering ...

5 months ago - Business Wire

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the ...

5 months ago - Business Wire

Bellus (BLU) Stock Surges on Data From Chronic Cough Study

Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.

5 months ago - Zacks Investment Research

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its s...

5 months ago - Business Wire

Here's Why Bellus Health Is Jumping Higher Today

A phase 2 trial with the company's chronic-cough candidate hit its primary endpoint.

5 months ago - The Motley Fool

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today

BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. The post BLU Stock Alert: The Study Data That Has BELLUS Health Blasting H...

5 months ago - InvestorPlace

BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refr...

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

5 months ago - Business Wire

Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Bellus Health (BLU) Reports Q3 Loss

Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

6 months ago - Business Wire

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

6 months ago - Business Wire

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...

Other symbols:ATRXCYDYDFFNENTX
7 months ago - InvestorPlace